Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Fig. 3

Adherence to treatment and scheduled study visits by randomised patients. Swimmer plots to visualise adherence to treatment and attendance at scheduled study visits of patients randomised to receive HMB/Arg/Gln (A) or patients randomised receive no HMB/Arg/Gln (B). The pathway of each individual patient is represented by a horizontal line and relevant outcome/symbols as per the key. HMB/Arg/Gln, β-Hydroxy β-Methylbutyrate/Arginine/Glutamine; LBM, lean body mass

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us